SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 3,537.33 |
| Book Value / Share | 33.86 |
| Price / Book | n/a |
| NCAV ($M) | 1,935.47 |
| NCAV / Share | 18.53 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.20 |
| Return on Assets (ROA) | -0.15 |
| Return on Equity (ROE) | -0.21 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.09 |
| Current Ratio | 2.32 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4,203.41 |
| Assets | 5,805.27 |
| Liabilities | 2,267.95 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,458.78 |
| Operating Income | -1,208.55 |
| Net Income | -881.71 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -1,157.45 |
| Cash from Investing | 60.00 |
| Cash from Financing | 416.48 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Oyler John | 5.20 | 2.05 | |
| 13D/A | Baker Bros. Advisors Lp | 10.20 | -9.35 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 86,880 | 372,509 | 23.32 | |
| 53,616 | 83,848 | 63.94 | |
| 46,809 | 71,798 | 65.20 | |
| 30,700 | 52,289 | 58.71 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ABUS – Arbutus Biopharma Corporation | ACAD – ACADIA Pharmaceuticals Inc. |
| ACLX – Arcellx, Inc. |
Financial data and stock pages provided by
Fintel.io